FDAs Sarepta在被裁定为不相关死亡后,清除了Duchenne肌肉萎缩基因治疗。 FDA clears Sarepta's Duchenne muscular dystrophy gene therapy after death ruled unrelated.

林业发展局已允许萨雷普塔治疗机构恢复其基因疗法Elevidis的运输,该疗法是为仍然能走路的Duchenne肌肉萎缩症患者提供的。 The FDA has allowed Sarepta Therapeutics to resume shipping its gene therapy, Elevidys, for Duchenne muscular dystrophy patients who can still walk. 这是在对一名8岁病人最近死亡的调查之后进行的,这名病人被发现与治疗无关。 This follows an investigation into the recent death of an 8-year-old patient, which was found to be unrelated to the therapy. Sarepta疗养院的股份在宣布后上升了16%以上。 Shares of Sarepta Therapeutics rose over 16% after the announcement. Elevidys是美国为杜尚肌肉萎缩 批准的第一种基因疗法。 Elevidys is the first gene therapy approved in the US for Duchenne muscular dystrophy. 美国食品和药物管理局仍需要更多关于老年患者的安全数据. The FDA still requires more safety data for older, non-ambulatory patients.